Národný Onkologický Program (NOP)

Objectives

The National Oncology Programme is Slovakia’s comprehensive cancer-control framework for reducing cancer incidence and mortality and improving quality of life through equitable, evidence-based prevention, early detection, diagnosis, treatment, survivorship, palliative care, research and outcome assessment.[1]Its five action areas cover primary prevention; secondary prevention and screening; diagnosis, treatment and supportive or terminal care; research, development and education; and health data and information.[2]

• Reduce exposure to modifiable cancer risks through health literacy, healthy diet and physical activity, tobacco and alcohol controls, environmental action, human papillomavirus vaccination and implementation of the European Code Against Cancer.[3][4][5]
• Establish high-quality population-based screening for breast, cervical and colorectal cancer, actively invite 90% of the target population, and develop evidence-based proposals for lung, prostate and stomach cancer screening.[6]
• Improve early diagnosis, timely treatment and access to comprehensive oncology centres, with an explicit target for 90% of patients with relevant needs to receive adequate treatment in such a centre.[7]
• Develop specialist capacity for personalised medicine, molecular diagnostics, reference and robotic surgery, CAR-T-cell therapy, clinical trials, paediatric oncology, survivorship and late-effects care.[7][8][9]
• Provide survivorship, psychosocial, rehabilitation, palliative, hospice and terminal care consistent with international clinical standards, while supporting carers, return to work and the rights of people with disabilities.[10]
• Strengthen translational, clinical and biomedical research, academic clinical trials, biobanking, international collaboration and the use of genomics, registry and other health data.[11][12][13]
• Modernise cancer information by improving mandatory reporting, automating data collection, reducing the cancer-data reporting delay and enabling screening and registry evaluation.[14][15]

The programme aligns Slovakia with the European Beating Cancer Plan and Horizon Europe Cancer Mission, which emphasise prevention, early detection, diagnosis, treatment, quality of life, research, innovation, digitalisation and new technologies.[16][17]Prevention is presented as a particularly cost-effective intervention, although the source notes that it receives an average of only 3% of health budgets across the European Union despite around 40% of cancers being preventable.[2]

Priority outcomes include stronger uptake and quality of screening, reduced mortality from selected cancers, modernised diagnostic and therapeutic pathways, improved access to innovative treatment, greater workforce capability, better survivorship support, and timely data for professional and policy decisions.[18][19][14]The programme also recognises the need to assess the effects of COVID-19-related disruptions to cancer diagnosis, treatment and palliative care across cancer groups and localities.[16]

Implementation

Implementation is organised through action plans for 2021–2025, coordinated nationally by the Ministry of Health of the Slovak Republic and the National Oncology Institute, with active participation by patient organisations, public-health bodies, health insurers, healthcare providers, professional societies, researchers and other partners.[17][20][21]The National Oncology Institute coordinates and implements action plans, supports screening quality control and research activity, and is expected to issue an annual report on its activities and implementation progress.[21]

• Establish and operate a National Oncology Screening Centre within the National Oncology Institute to coordinate invitations, delivery, quality control, monitoring, evaluation and updating of screening programmes.[22][23]
• Use health-insurer invitations for people not reached through preventive examinations, integrate opportunistic and invitation-based screening, and support participation through targeted public communication and possible incentives for clinicians and citizens.[24]
• Maintain the National Screening Register within the National Centre for Health Information and create data flows from providers through health insurers to national information, oncology, ministry and scientific bodies.[22]
• Certify and recertify screening facilities, publish quality-control procedures and service networks, and prepare annual quality-control, evaluation and cost-analysis reports for programme guarantors and the Ministry of Health.[25][26]
• Concentrate highly specialised interventions in specialist centres while retaining accessible local oncology provision for chronic and palliative care, supported by interdisciplinary teams that include psychological and social care.[7][27]
• Implement diagnostic algorithms for tissue and liquid biopsies, next-generation sequencing in selected centres, internationally recognised External Quality Assurance, and quality controls for diagnostic and surgical treatment.[28][29]
• Develop research infrastructure through SLOVACRIN, the Slovak Cooperative Oncology Group, BIOHUB SK, biobank networks and international partnerships, while providing clinical-trial training, mentoring, technology-transfer support and legislative reform.[11][30][31][32]
• Automate cancer-reporting and screening-data processes by reusing eHealth data, pre-filling mandatory reports, mapping data sources, expanding survival analysis and enabling legally compliant access to pseudonymised registry data.[33][34][35]

Governance combines ministerial leadership with operational responsibility across named institutions. The Ministry of Health guarantees population screening and provides methodological, legislative and financial direction, while the National Oncology Institute coordinates and evaluates programmes.[22][36]The National Centre for Health Information manages core registry functions, public-health authorities lead prevention work, and health insurers support invitations, reimbursement and data transfers.[37][22][36]Cross-sectoral collaboration is intended to follow a health-in-all-policies approach and involve environment, education, agriculture, social-care, research and civil-society stakeholders where relevant.[17][37][38]

Monitoring mechanisms include annual prevention-activity counts, human papillomavirus vaccination coverage, screening quality-control reports, clinical and epidemiological screening parameters, access to registry data, research-call and grant counts, clinical-trial training participation, and data coverage and timeliness measures.[37][18][25][39][32][15]Baseline human papillomavirus vaccination coverage is 23% among girls and 1% among boys.[37]Wider common indicator definitions, reporting templates and independent accountability arrangements are not consistently specified across all programme areas.[40][14]

Financing combines Ministry of Health appropriations, National Oncology Institute and National Centre for Health Information budgets, health-insurance reimbursement, European Union programmes, the Recovery and Resilience Plan and other external sources.[26][8][28][35]Explicit investments include 12,000,000 euros for a tertiary surgical oncology referral centre, 600,000 euros for a CAR-T-cell treatment centre, 250,000 euros for a survivors’ clinic, 1,800,000 euros for thematic oncology research grants, and 3,666,000 euros from the Ministry of Health chapter for selected research-infrastructure activities during 2021–2025.[8][9][39][32]The document does not provide a consolidated national programme budget or quantified funding gap.[19][41]

Monitoring & Evaluation

The programme combines population-level cancer prevention, screening, treatment quality, research and health-data systems, but monitoring maturity varies by action area. Stronger arrangements are defined for organised screening, cancer registries and selected research activities; several treatment, survivorship and research measures lack complete indicator sets, reporting cycles or independent accountability mechanisms.[37][18][14][10]

• Monitor primary prevention through the annual number of completed activities and human papillomavirus vaccination coverage among girls and boys; baseline coverage is 23% for girls and 1% for boys.[37]
• Coordinate, monitor and evaluate breast, cervical and colorectal screening through the National Oncology Screening Centre and National Screening Register, using defined data flows between providers, insurers, the National Centre for Health Information, the National Oncology Institute and the Ministry of Health.[22]
• Assess screening quality and effectiveness regularly using population, clinical and epidemiological parameters, supported by legally compliant and secure data flows, full expert access to the screening-register database, annual quality-control reports, evaluation reports and cost analyses.[18][25][26]
• Maintain continuous quality control and evaluation of organised screening programmes, including short- and long-term performance parameters; the Ministry of Health is programme guarantor and the National Oncology Institute coordinates evaluation and reports to it.[36]
• Improve cancer surveillance by automating National Cancer Registry reporting, processing and validation, expanding analytical outputs including survival data, reducing reliance on manual case-finding and addressing the stated five-year data delay.[14][15][35]
• Produce regular or ad hoc pseudonymised registry analyses for the Ministry of Health, the National Oncology Institute, professional bodies and other authorised users, subject to applicable law.[35]
• Apply external quality assurance to contracted diagnostic centres and use digital patient-reported outcomes for symptom monitoring, communication and care-quality assessment.[28][42]
• Track research delivery through annual updates to clinical-trial and infrastructure roadmaps, numbers of calls, grants, working meetings, trained personnel, start-ups, patents and technology-transfer activities.[31][39][32]
• Report annually on National Oncology Institute activities and implementation of National Oncology Programme action plans.[21]

Explicit outcome targets include adequate comprehensive-oncology-centre treatment for 90% of patients with relevant needs and passive digital cancer-case data coverage above 90%.[7][15]Wider quantitative indicators, standard reporting templates, sanctions and independent evaluation arrangements are not consistently specified, particularly for survivorship, palliative care and several diagnostic, treatment and research actions.[10][19][13]

Costing & Financing

Financing combines Ministry of Health allocations, National Oncology Institute and National Centre for Health Information budgets, public health insurance, European Union instruments and the Recovery and Resilience Plan. Identified allocations support prevention, screening, treatment capacity, diagnostics, research, biobanking, data systems and National Oncology Institute coordination, although many activities have no stated monetary value and no consolidated programme budget is provided.[37][8][31][21]

• Allocate 600,000 EUR each to two primary-prevention activities for 2022–2025, equivalent to 150,000 EUR annually for each activity; vaccination is financed through public health insurance and EU4Health provides additional support.[37]
• Provide 1,600,000 EUR from the Ministry of Health budget for 2021–2025 for screening-related action, equivalent to 320,000 EUR annually; this includes 400,000 EUR for National Oncology Institute calls supporting non-governmental organisations during 2022–2025.[43]
• Fund colorectal and cervical screening invitations and procedures through health insurance, while financing colorectal quality control, screening-centre implementation and programme evaluation from the National Oncology Institute budget.[25][26]
• Invest 600,000 EUR in a CAR-T-cell treatment centre, 12,000,000 EUR in a tertiary surgical oncology referral centre, 250,000 EUR in a survivors’ clinic and 2,000 EUR in an expert proposal on innovative-treatment approval.[8][9]
• Assign 52,000 EUR for diagnostic and surgical quality activities during 2021–2025, including 10,400 EUR annually from the Ministry of Health; external diagnostic quality-assurance fees are financed through health insurance.[29]
• Support research infrastructure through 3,666,000 EUR from the Ministry of Health chapter for 2021–2025, including biobanking, research grants and mentoring; additional funding is identified through EU, recovery-plan and operational-programme sources.[31][39][32]
• Provide annually increasing National Oncology Institute coordination funding from 493,500 EUR in 2021 to 613,500 EUR in 2025.[21]

European-level context includes a 5.1 billion EUR EU4Health programme for 2021–2027, while prevention is reported to receive an average 3% of European Union health budgets despite around 40% of cancers being preventable.[17][2]Funding gaps include insufficient hospice and mobile-hospice reimbursement, limited systematic support for academic research and incomplete costing for numerous screening, survivorship, data and treatment measures.[44][45][14]